Array ( [slideid] => 2 [autoload] => 1 [effect] => scrollUp [speed] => 5000 [width] => 470 [height] => 124 )

Array ( [slideid] => 1 [autoload] => 1 [effect] => fade [speed] => 10000 [width] => 600 [height] => 284 )
  • Roadmap for delivering Quality Stroke Care

  • WSO's strategy

    Since September last year the Executive and Board of WSO have been working on the development of a strategy for WSO. Please click here to download a concise version of the strategy which highlights out vision, mission, direction towards 2020 and WSO's overarching priorities.
  • Toolkit for the Global Bill of Rights

    Be part of a global campaign to save the 6 million lives lost to stroke and to improve the recovery of 11 million stroke survivors each year. At the heart of this campaign is the Global Stroke Bill of Rights, which sets out aspects of care that are important for ALL stroke survivors and caregivers from across the world. The document was developed by the World Stroke Organization, in partnership with stroke survivors and their caregivers. It sets out the right of each person to: 1.Receive the best stroke care 2.Be informed and prepared 3.Be supported in their recovery How can I use the Stroke Bill of Rights? The Stroke Bill of Rights can help individuals to discuss the care, services and support they need with those providing their care. The document is also an important campaign tool for organzisations when they communicate with stroke care providers and with governments. You can use it to advocate for effective treatment and care and to increase awareness and understanding of what people affected by stroke think are the most important things for their recovery. How can I get involved? Read it! download a copy of the Global Stroke Bill of Rights Sign it! – sign the online petition and join the campaign Share it!– share the document and the petition with your friends, family and networks

wso play The World Stroke Academy (WSA) is a elearning portal for the World Stroke Organization (WSO). it provides stroke information on a dynamic, and award-winning online, elearning platform for healthcare professionals with an aim to alleviate the global burden of stroke through the education of stroke practitioners worldwide.
WSC-One-Voice-Logo resizedThe theme for World Stroke Day 2016 is Face the Facts: Stroke is Treatable with the tagline of: Lives can improve with better awareness, access, and action. Stroke can happen to anyone at any age. World Stroke Day 2016 recognizes that although stroke is a complex medical issue, there are ways to significantly reduce its impact.

Montreal, Canada, October 17- 20, 2018
Through its biennial congresses, the World Stroke Organization (WSO) strives to offer participants opportunities to refine their skills and knowledge in the field of stroke, as well as providing excellent networking opportunities and strengthening scientific collaborations to improve the care of stroke victims throughout the world.
IJS edited
The International Journal of Stroke (IJS) is the flagship publication of the World Stroke Organization (WSO) and publishes high quality research articles, reviews and clinical trial protocols from around the world. IJS is dedicated to building a global stroke community, making it a global voice for stroke research and an excellent platform for sharing international stroke research.
Stay connected with us through Twitter, the WSO blog, and YouTube!

Global Stroke Guidelines and Action Plan: A Road Map for Quality Stroke Care. Download here!


Your membership makes the difference!

Latest Podbean

Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial) - Rationale and study design Tobias Geisler


 Article link here

Optimal secondary prevention of embolic stroke of undetermined source (ESUS) is not established. The current standard in these patients is acetylsalicylic acid (ASA), despite high prevalence of yet undetected paroxysmal atrial fibrillation (AF).

ESUS is caused by embolic disease and associated with a high risk of recurrent ischemic strokes and clinically silent cerebral ischemic lesions. The ATTICUS randomized trial will investigate the impact of AF detected by ICM and the effects of early anticoagulation with apixaban compared to antiplatelet therapy with ASA on the incidence of NIL after ESUS.

I’m Carmen Lahiff-Jenkins Managing Editor of the International Journal of Stroke and I spoke to Tobias Geisler, lead author for the Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial) - Rationale and study design published i [...]

See all